viDA is creating novel drugs for the treatment of inflammatory and autoimmune diseases based on our cutting-edge work in the field of granzymes.

Alistair Duncan is co-Founder, President, and Chief Executive Officer of viDA Therapeutics Inc. Prior to viDA, Alistair co-founded and served as President and CEO of Chromos Molecular Systems Inc., developing artificial chromosome technology for cellular protein production and cell/gene therapy applications.  Alistair also co-founded, and served as Director, Chief Financial Officer for Agrisoma Biosciences Inc., building high performance crop seeds for renewable fuels.  Alistair previously served as a Principal with E&Y’s Corporate Finance and International Life Sciences Group.

He is a 25-year industry veteran having held diverse positions across commercial operations, business development, strategy, and innovation.  Alistair is known for his passion for innovation and development of breakthrough technologies and business opportunities. He holds a Bachelor of Science in biochemistry from the University of British Columbia and is a member of the Institute of Chartered Accountants of British Columbia. He served as Chairman and Board Member for the following organizations: the Michael Smith Foundation for Health Research, BC Technology Industry Association, BC Research Institute for Children’s and Women’s Health, and BC Biotech (now LifeSciences BC).

Dr. Granville is a co-Founder and serves as the Company’s Chief Scientific Officer (CSO) Dr. David Granville is a Full Professor and Associate Dean, Research in the Faculty of Medicine at the University of British Columbia (UBC). He also serves as the Executive Director of the Vancouver Coastal Health Research Institute (VCHRI), the largest hospital-based research institute in Western Canada. He is also a Principal Investigator and Director of the BC Professional Firefighters’ Burn and Wound Healing Research Laboratory, VCHRI. He completed his Ph.D. at UBC and his post-doctorate work at The Scripps Research Institute, San Diego, CA. Dr. Granville previously worked at QLT, Inc. (1994-2001) where his R&D studies supported the approval of Visudyne® to be used as the first treatment for macular degeneration, the leading cause of blindness in the elderly. In 1999 Visudyne® was approved by the FDA resulting in the largest ophthalmic product release in history. Dr. Granville’s research is referred to on the drug label for Visudyne®. In 2001, Dr. Granville moved to Scripps where he discovered a novel therapeutic approach for cardiac ischemia and reperfusion injury, which led to the formation of Radical Therapeutix (San Diego, CA). He was recruited back to UBC as an Assistant Professor, Canada Research Chair and Michael Smith Foundation for Health Research Scholar in 2003. In 2016 he was recruited to VCHRI where he currently resides. Dr. Granville has received numerous awards including a Canada Research Chair, Canada Top 40 Under 40 Award, Business in Vancouver Forty Under 40, Canadian Association of Pathology Scientist Award, 2006 UBC Outstanding Young Alumnus Award, the 2007 SFU Academic Alumnus Award, and was a runner-up for the 2007 American Heart Association Louis and Arnold Katz Basic Science Prize. He is also a Fellow of the American Heart Association and a Scholar of the Royal Society of Canada. More recently Dr. Granville was the recipient of the prestigious Canadian Institutes for Health Research Institute of Aging Excellence in Research Prize (2022).

Specializing in R&D, operations, and corporate strategy within the pharmaceutical, biotech, and contract research industries, Harry has held a number of VP/C-Level executive positions. Harry’s diverse R&D experience encompasses small and large molecules, advanced therapies like cell and gene therapies, and engineered tissues. He has led cross-functional teams through all stages of product and platform development, from discovery to human proof of concept, commercial launch, and divestiture. Additionally, Harry has extensive experience in corporate strategic planning, execution, performance management, and building strong relationships with clients, contractors, and strategic partners. Harry has Doctor of Philosophy (PhD) in Molecular & Cell Biology from Penn State University and a Bachelor of Science (BS) in Biochemistry from The Ohio State University.

Mr. Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.

Dr. Cameron serves as Associate Director, Medicinal Chemistry, and nominal Head of Drug Discovery.  His professional experience over the past 18 years includes a variety of roles in Computational Chemistry, Medicinal Chemistry and Intellectual Property (IP) at small and large pharmaceutical companies and as a private consultant.  From 2009 to 2012 he operated as a consultant to two companies in a variety of roles including computational chemistry, intellectual property, and business development support.  Prior to that he served in several roles at local biotech company, MIGENIX (Micrologix Biotech), most recently as Director, Research (Anti-Infectives) and Manager, Intellectual Property (in a concurrent role) and was responsible for Drug Discovery Research activities in antibacterial, anti-viral, and anti-fungal programs. He also managed the IP portfolio and other roles including evaluation of potential licensing opportunities.  Prior to this Dr. Cameron spent almost 6 years at Boehringer Ingelheim (Canada) Ltd, in Laval, QC where he most recently served as the Head of Structural Research as a Sr. Research Scientist in Computational Chemistry.  In this he was awarded, as part of a team, the 2000 Boehringer Ingelheim R&D Award for his role in the identification of BILN2061, the first Hepatitis C Virus Protease inhibitor to proceed to human clinical trials. He is coauthor on over 30 scientific publications and is named as inventor on at least 12 patent families.  He has a Bachelor of Science (Hons., Subject of Specialization) in Chemistry and a Ph.D. in Chemistry both from Queen’s University.

With more than 20 years of biotech and pharmaceutical experience, Mary Jane brings expertise on buy and sell side, mergers & acquisitions, equity investment, business development, licensing and corporate strategy, at multinational pharma companies and US private and global small midcaps and value-creating transformative transactions. MaryJane has a PhD from Cardiff University, Wales, United Kingdom in NeuroOphthalmology and an Executive MBA from INSEAD in Paris France and a Master of Science in Immunology from Stanford University, Palo Alto. She obtained a Bachelor of Science in Molecular Biology from University of Southern California Los Angeles, CA.